20 April 2021: Original Paper
Long-Term Outcomes of Early Experience in Donation After Circulatory Death Liver Transplantation: Outcomes at 10 Years
Omar J. Haque 12ADEF , Eve M. Roth 12ADEF , Aaron Fleishman 12ABCDE , Devin E. Eckhoff 12ADG* , Khalid Khwaja 12ADEG*DOI: 10.12659/AOT.930243
Ann Transplant 2021; 26:e930243
Table 2 Liver transplant donor and recipient characteristics reweighted using stabilized inverse probability of treatment weights (sIPWs).
| Characteristic | DBD (n=27 483) | DCD (n=1194) | SD* |
|---|---|---|---|
| Age in years, mean (standard deviation) | 41.4 (17.5) | 40.3 (17.4) | 0.06 |
| Sex, Female, n (%) | 10 977 (40.0) | 515 (43.2) | 0.067 |
| Race, n (%) | 0.078 | ||
| Non-Hispanic white | 18 918 (68.9) | 812 (68.2) | |
| Black | 4 228 (15.4) | 213 (17.9) | |
| Other | 4 293 (15.6) | 166 (13.9) | |
| BMI in kg/m, median (q1–q3) | 25.7 (22.7–29.5) | 25.3 (22.3–29.7) | 0.035 |
| Cause of death, n (%) | 0.093 | ||
| Anoxia | 3 966 (14.5) | 209 (17.6) | |
| Cerebrovascular/stroke | 11 854 (43.2) | 479 (40.3) | |
| Head trauma | 10 892 (39.7) | 467 (39.2) | |
| Other6 | 727 (2.6) | 36 (3.0) | |
| History of smoking, n (%) | 0.008 | ||
| Yes | 9020 (32.9) | 395 (33.2) | |
| No | 18 131 (66.1) | 783 (65.8) | |
| Unknown | 288 (1.1) | 13 (1.1) | |
| History of diabetes, n (%) | 0.048 | ||
| Yes | 2 542 (9.3) | 94 (7.9) | |
| No | 24 784 (90.3) | 1 091 (91.6) | |
| Unknown | 112 (0.4) | 6 (0.5) | |
| History of hypertension, n (%) | 0.039 | ||
| Yes | 8 753 (31.9) | 375 (31.5) | |
| No | 18 513 (67.5) | 804 (67.5) | |
| Unknown | 173 (0.6) | 12 (1.0) | |
| History of previous MI, n (%) | 0.091 | ||
| Yes | 937 (3.4) | 59 (4.9) | |
| No | 22 282 (81.2) | 930 (78.1) | |
| Unknown | 4 220 (15.4) | 202 (17.0) | |
| Total cold Ischemic Time in hours, median (q1–q3) | 7.0 (5.3–9.0) | 6.7 (5.2–9.0) | 0.044 |
| CDC high risk | 0.062 | ||
| Yes | 1 679 (6.1) | 90 (7.5) | |
| No | 18 294 (66.7) | 795 (66.7) | |
| Unknown | 7 465 (27.2) | 306 (25.7) | |
| Anti-CMV status | 0.046 | ||
| Positive | 17 867 (65.1) | 773 (64.9) | |
| Negative | 9 439 (34.4) | 408 (34.2) | |
| Unknown | 133 (0.5) | 10 (0.9) | |
| HCV antibody status | 0.037 | ||
| Positive | 792 (2.9) | 38 (3.2) | |
| Negative | 17 027 (62.1) | 718 (60.3) | |
| Unknown | 9 620 (35.1) | 435 (36.5) | |
| Age in years, mean (standard deviation) | 52.9 (10.0) | 52.7 (9.8) | 0.016 |
| Sex, female, n (%) | 8 820 (32.1) | 417 (35.1) | 0.062 |
| Race, n (%) | 0.029 | ||
| Non-Hispanic White | 20 001 (72.9) | 883 (74.2) | |
| Black | 2 433 (8.9) | 102 (8.6) | |
| Other | 5 005 (18.2) | 205 (17.3) | |
| BMI in kg/m, median (q1–q3) | 27.4 (24.1–31.5) | 27.1 (23.9–30.7) | 0.079 |
| Primary diagnosis | 0.088 | ||
| Biliary disease | 2 416 (8.8) | 126 (10.5) | |
| Liver disease | 19 609 (71.5) | 851 (71.5) | |
| Metabolic | 724 (2.6) | 29 (2.5) | |
| Tumor | 3 914 (14.3) | 145 (12.1) | |
| Other | 776 (2.8) | 40 (3.4) | |
| Blood type | 0.099 | ||
| A | 10 224 (37.3) | 431 (36.2) | |
| B | 3 633 (13.2) | 127 (10.6) | |
| AB | 1 393 (5.1) | 75 (6.3) | |
| O | 12 118 (44.4) | 558 (46.8) | |
| INR, median (q1–q3) | 1.6 (1.3–2.0) | 1.6 (1.3–2.0) | 0.002 |
| Serum creatinine in mg/dl, median (q1–q3) | 1.1 (0.8–1.6) | 1.1 (0.8–1.6) | 0.002 |
| Total bilirubin in mg/dl, median (q1–q3) | 3.4 (1.7 7.9) | 3.6 (1.8–7.7) | 0.019 |
| Calculated model for end-stage liver disease (MELD) score, median (q1–q3) | 17 (11–27) | 17 (12–26) | |
| HCC exception | 0.068 | ||
| Yes | 6 504 (23.7) | 248 (20.9) | |
| No | 20 934 (76.3) | 942 (79.1) | |
| Anti-CMV status | 0.045 | ||
| Positive | 16 566 (60.4) | 741 (62.2) | |
| Negative | 7 660 (27.9) | 323 (27.2) | |
| Unknown | 3 212 (11.7) | 126 (10.6) | |
| SD – standardized difference, * a value | |||